Xtoro ® (finafloxacin otic suspension), 0.3% is now available for the treatment of acute otitis externa (AOE) caused by susceptible strains of Pseudomonas aeruginosa and Staphylo ...
Fonseca Biosciences, a specialty pharmaceutical company commercializing clinically differentiated pharmaceutical products, today announced the launch of XTORO® (finafloxacin otic suspension), 0.3% for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results